Hyperuricemia on Hypertension and Metabolic Syndrome

Effect of Hyperuricemia Treatment on Hypertension and Metabolic Syndrome

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01157936

Enrollment

Registered

2010-07-08

Start date

2010-07-31

Completion date

2011-08-31

Last updated

2014-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Enzymes, Metabolic Syndrome Parameters, Systolic and Diastolic Blood Pressure Levels, Uric Acid Levels

Keywords

hypertension, hyperuricemia, metabolic syndrome

Brief summary

The purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.

Detailed description

Elevated consumption of high fructose corn syrup has lead to an increase of 30% of fructose intake since the last 20 years. Important data supporting this fact can be reflected on incidence and prevalence of Metabolic syndrome and hyperuricemia. A peculiar effect of fructose intake demonstrated in animal models is the development of elevated uric acid levels; also some studies have found a clear association between hyperuricemia as an important risk factor for hypertension, diabetes mellitus, chronic kidney disease and metabolic syndrome. Taking into account the existing evidence, our clinical research team presents this protocol as a way to evaluate the effect of uric acid treatment and its relation with Fructose consumption, metabolic syndrome parameters, hyperuricemia and risk of hypertension. Confirming evidence with clinical basis may be the initial strategy to create primary prevention programs to control this health problems affecting Mexican Population.

Interventions

DRUGAllopurinol

daily dosage

OTHERplacebo

daily dosage

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

25 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* adults with blood pressure from 120/80 mmHg and less than 140/90 mmHg * no pharmacological treatment for blood pressure control

Exclusion criteria

* hypertension (more than 140/90mmHg) * Diabetes Mellitus type 1 or 2 * Chronic kidney disease (MDRD less than 60) * Hepatic Disease * Malignancy * Pregnancy * patient receiving any medication

Design outcomes

Primary

Measure	Time frame	Description
Effect of hyperuricemia treatment on systemic blood pressure	14 weeks	participants will be randomized to a 4 week placebo versus alopurinol treatment followed by a wash out period. After crossover them, they will receive the complementary pharmacological intervention for another 4 weeks.

Secondary

Measure	Time frame	Description
Effect of hyperuricemia treatment on metabolic syndrome parameters	14 weeks	baseline and final laboratory samples during pre and post crossover periods will include metabolic syndrome measurements (triglycerides, cholesterol, glucose and abdominal perimeter).

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026